ARTICLE IN REVIEW:

ViviGen® outperformed conventional MSC-based cellular bone allografts in clinical and patient-reported outcomes in ankle arthrodesis procedures

**Significantly higher ankle fusion rates:**

At 6 months postoperative, the rate of ankle fusion in patients treated with ViviGen Cellular Bone Matrix was double that of patients treated with Trinity (100% vs. 50%; p<0.0001).

**Effective despite comorbidities:**

In diabetic patients and tobacco-users, successful ankle fusion was achieved in 100% of ViviGen patients (9/9 diabetic patients, 5/5 tobacco-users) compared with 50% of Trinity patients (3/6 diabetic patients, 2/4 tobacco-users).

**Significantly lower postoperative pain and complications:**

Postoperatively, patients treated with ViviGen reported significantly greater satisfaction and lower pain (100% vs 68.75% and mean VAS=1.4 vs 3.15; p<0.01). The rate of complication in ViviGen was approximately one-tenth that of Trinity (6.45% vs 62.5%; p<0.0001). Complications in the ViviGen group were solely due to hardware failure, while those in the Trinity group included hardware failure, nonunion, infection and amputation.

---

**Superior Clinical and Patient-Reported Outcomes with ViviGen**

![Graph showing comparison between ViviGen and Trinity for fusion at 6 months, satisfaction, and complications](Figure 2 and Figure 3 adapted and reproduced with permission.)

---

*Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.*

68-20-315-0100

LifeNet Health, the LifeNet Health logo, and ViviGen are registered trademarks of LifeNet Health. ©2020 LifeNet Health, Virginia Beach, VA. All rights reserved.

DePuy Synthes 2020. All rights reserved.

152483-200909 DSUS

The third party trademarks used herein are the trademarks of their respective owners.